Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study

S H Fatemi, Mahtab K. Yousefi, Rachel E. Kneeland, Stephanie B. Liesch, Timothy D. Folsom, Paul D. Thuras

Research output: Contribution to journalLetterpeer-review

20 Scopus citations
Original languageEnglish (US)
Pages (from-to)376-378
Number of pages3
JournalSchizophrenia Research
Issue number1-3
StatePublished - May 2013

Bibliographical note

Funding Information:
Grant support from the National Institute on Drug Abuse (grant # R01DA024674-01A1 ) to SHF is gratefully acknowledged. We would like to thank all the participants in this clinical trial; Dr. Darlette Luke of the University of Minnesota Medical Center, Fairview Compounding Pharmacy for her assistance in dispensing medication and in the randomization of patients and Dr. Michael Kotlyar from the University of Minnesota College of Pharmacy for helpful comments. Pfizer provided free samples of varenicline and placebo and had no role in design or conduct of this study. Watson Laboratories provided free samples of Bupropion SR. All authors have no conflict of interest to declare.

Cite this